First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer

Anticancer Res. 2007 May-Jun;27(3B):1641-4.

Abstract

Aim: To assess the practical efficacy of low-dose leucovorin plus 5-fluorouracil (LV/5-FU) in elderly patients with metastatic colorectal cancer.

Patients and methods: The records of 20 patients treated with LV/5-FU for unresectable metastatic disease from colorectal cancer from 1999 to 2004 were retrospectively reviewed. The patients received LV/5-FU as first-line, and low-dose CPT-11 and CDDP regimen (CPT-11/CDDP) as second-line therapy.

Results: In the treatment of LV/5-FU, no patients had CR, 3 patients had PR, 4 patients had SD and 13 patients had PD, which results in a response rate (RR) of 15% and in a disease control rate (DCR) of 35%. MST of all patients was 18.4 months. There was one patient who experienced grade 3 or 4 adverse reactions during the course of these regimens.

Conclusion: Low-dose LV/5-FU chemotherapy in elderly patients with metastatic colorectal cancer could be acceptable in order to avoid adverse effects and to obtain quite a favorable survival time.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / mortality*
  • Colorectal Neoplasms / pathology
  • Female
  • Fluorouracil / administration & dosage*
  • Humans
  • Leucovorin / administration & dosage*
  • Male
  • Neoplasm Metastasis
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Leucovorin
  • Fluorouracil